A Phase I/II Study of NPC-22 in Patients with Amyotrophic Lateral Sclerosis (NPC-22-4)
Latest Information Update: 06 Nov 2023
At a glance
- Drugs Scopolamine (Primary)
- Indications Sialorrhoea
- Focus Adverse reactions
- Acronyms NPC-22-4
- Sponsors Nobelpharma
Most Recent Events
- 06 Nov 2023 New trial record